Company news
North China Pharmaceutical Company Ltd. Class A (SSE:600812) news
North China Pharmaceutical Company Ltd. Class A news releases on 6ix. Latest, Sep 10, 2026: "North China Pharmaceutical Company Ltd."Announcement on Attending…
Press releases & updates
"North China Pharmaceutical Company Ltd."Announcement on Attending the 2026 Online Collective Reception Day for Investors of Listed Companies in Hebei Jurisdiction and 2026 Semi-annual Collective Performance Briefing
September 9, 2026
"North China Pharmaceutical Company Ltd."Announcement on Providing Guarantees for Subsidiaries
September 2, 2026
"North China Pharmaceutical Company Ltd."Announcement on Obtaining Notice of Approval for Drug Supplementary Application by a Subordinate Company
August 27, 2026
"North China Pharmaceutical Company Ltd."Semi-annual Report for 2026
August 21, 2026
"North China Pharmaceutical Company, Ltd."Announcement on Resignation of Senior Management
August 5, 2026
"North China Pharmaceutical Company Ltd."Announcement on the Proposed Selection of Drugs of the Company and Its Subsidiaries in the National Centralized Drug Procurement
August 3, 2026
"North China Pharmaceutical Company.Ltd"Announcement on Inclusion of Products of the Company and Its Subsidiaries in the National Essential Medicines List
July 10, 2026
Announcement on Obtaining Drug Registration Certificate
June 23, 2026
Announcement on Implementation of Dividend Distribution for 2025
June 4, 2026
Announcement on Election of Employee Director
May 20, 2026
Announcement on Convening Performance Briefing for 2025 and Q1 2026
May 7, 2026
Announcement on Release of Pledge and Pledge of Some Shares of Shareholders
April 28, 2026
Notice on Convening the 2025 Annual General Meeting
April 24, 2026
Announcement on Renewing Engagement of Accounting Firm
April 17, 2026
Announcement on Receipt of Government Land Acquisition and Sale Proceeds Return Payments
April 3, 2026
Announcement on Obtaining the Drug Registration Certificate by Subsidiary
February 9, 2026
Announcement on Providing Guarantee for Subsidiary
February 2, 2026
Announcement on Wholly-owned Subsidiary's Passing GMP Compliance Inspection for Drugs
January 23, 2026
Announcement on Resolutions of the 26th Meeting of the 11th Board of Directors
December 29, 2025
Announcement on Resolutions of the 25th Meeting of the 11th Board of Directors
December 15, 2025
Announcement on Resolutions of the 24th Meeting of the 11th Board of Directors
November 28, 2025
Announcement on Convening the Q3 2025 Performance Briefing
November 19, 2025
Announcement on Cashing Completion of Phase I Short-term Financing Bonds of 2025
November 17, 2025
Announcement on Obtaining the Notice of Approval for Marketing Application of Chemical APIs by Subsidiary
November 4, 2025
Report for Q3 2025
October 24, 2025
Announcement on the Results of Issuance of the 2025 Phase I Science and Technology Innovation Bonds
October 23, 2025
Indicative Announcement on Postponing Election of Board of Directors at Expiry of Term of Office
October 10, 2025
Announcement on Attending 2025 Online Collective Reception Day for Investors of Listed Companies in Hebei Jurisdiction and 2025 Semi-annual Report Collective Performance Briefing
September 10, 2025
2025 Semi-annual Report
August 13, 2025
Announcement on Implementation of Dividend Distribution for 2024
July 18, 2025
Announcement on Receiving the Chemical Active Pharmaceutical Ingredient (API) CEP Certificate by Subsidiary
July 15, 2025
Announcement on Expected Increase in Semi-annual Performance for 2025
July 10, 2025
Announcement on Resolution of the 2024 Annual General Meeting
June 11, 2025
Announcement on Obtaining Notice of Approval for Drug Supplementary Application
June 5, 2025
Announcement on the Release of Pledge for Shares Held by the Controlling Shareholder
May 21, 2025
Announcement on Issuance Result of Phase I Short-term Financing Bonds in 2025
May 19, 2025
Announcement on Obtaining Notice of Approval for Drug Clinical Trials by Subsidiary
May 15, 2025
Announcement on Lifting the Freeze of Controlling Shareholder's Shares
May 13, 2025
Announcement on Pledge Release of Some Shareholders' Shares
May 7, 2025
Announcement on Resolution of the 14th Meeting of the 11th Board of Supervisors
April 23, 2025
Announcement on Change of Accounting Policies
March 27, 2025
Announcement on the Wholly-owned Subsidiary's Acquisition of the GMP Compliance Certificate Issued by AEMPS of Spain
March 12, 2025
Announcement on the Wholly-owned Subsidiary's Passing GMP Compliance Inspection
February 24, 2025
Announcement on Expected Increase in Annual Performance for 2024
January 16, 2025
Announcement on Receiving the Return of Income from Government Land Purchase, Reserve and Transfer and Signing the Supplementary Contract for Acquisition (Return) of State-owned Land Use Rights of Enterprises and Institutions
January 2, 2025
Announcement on Subsidiary's Withdrawal of Drug Registration Application
December 16, 2024